Omeros Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Omeros kazanç ve gelirinin sırasıyla yıllık 39.1% ve 68.8% oranında artması tahmin edilirken, EPS'nin yıllık 44.8% oranında büyümesi bekleniyor.

Anahtar bilgiler

39.1%

Kazanç büyüme oranı

44.8%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	21.3%
Gelir büyüme oranı	68.8%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	14 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:3O8 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	26	-126	N/A	N/A	2
12/31/2025	8	-147	N/A	N/A	2
12/31/2024	N/A	-170	N/A	N/A	2
9/30/2024	N/A	-185	-155	-155	N/A
6/30/2024	N/A	-200	-156	-155	N/A
3/31/2024	N/A	-179	-142	-142	N/A
12/31/2023	N/A	-175	74	75	N/A
9/30/2023	N/A	-182	84	84	N/A
6/30/2023	N/A	-185	90	90	N/A
3/31/2023	N/A	-182	103	103	N/A
12/31/2022	N/A	-182	-87	-86	N/A
9/30/2022	N/A	-183	-79	-79	N/A
6/30/2022	N/A	-173	-77	-77	N/A
3/31/2022	N/A	-181	-85	-85	N/A
12/31/2021	N/A	-192	-110	-110	N/A
9/30/2021	-63	-217	-110	-110	N/A
6/30/2021	-37	-211	-121	-121	N/A
3/31/2021	-24	-194	-131	-131	N/A
12/31/2020	N/A	-173	-100	-100	N/A
9/30/2020	97	-130	-105	-105	N/A
6/30/2020	100	-108	-78	-77	N/A
3/31/2020	114	-89	-56	-56	N/A
12/31/2019	N/A	-147	-60	-60	N/A
9/30/2019	100	-79	-62	-62	N/A
6/30/2019	75	-102	-92	-91	N/A
3/31/2019	50	-121	-106	-105	N/A
12/31/2018	30	-127	-104	-104	N/A
9/30/2018	22	-120	-84	-83	N/A
6/30/2018	39	-88	N/A	-58	N/A
3/31/2018	54	-68	N/A	-35	N/A
12/31/2017	65	-53	N/A	-36	N/A
9/30/2017	64	-57	N/A	-43	N/A
6/30/2017	54	-63	N/A	-43	N/A
3/31/2017	46	-61	N/A	-48	N/A
12/31/2016	42	-67	N/A	-52	N/A
9/30/2016	35	-67	N/A	-57	N/A
6/30/2016	27	-73	N/A	-61	N/A
3/31/2016	21	-77	N/A	-64	N/A
12/31/2015	14	-75	N/A	-65	N/A
9/30/2015	7	-76	N/A	-64	N/A
6/30/2015	4	-74	N/A	-66	N/A
3/31/2015	1	-76	N/A	-64	N/A
12/31/2014	1	-74	N/A	-58	N/A
9/30/2014	1	-55	N/A	-43	N/A
6/30/2014	1	-50	N/A	-38	N/A
3/31/2014	1	-46	N/A	-32	N/A
12/31/2013	2	-40	N/A	-30	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 3O8 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 3O8 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 3O8 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 3O8 şirketinin gelirinin (yıllık 68.8% ) German pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 3O8 şirketinin gelirinin (yıllık 68.8% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 3O8 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Omeros Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2024

Recent updates

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Omeros Corporation to Report Q3, 2024 Results on Nov 13, 2024

FDA Grants Rare Pediatric Disease Designation to Omeros' MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

New major risk - Financial position

Omeros Corporation to Report Q2, 2024 Results on Aug 07, 2024

Omeros Corporation Announces Executive Changes

Omeros Corporation announced that it expects to receive $92.1 million in funding

Omeros Corporation to Report Q1, 2024 Results on May 15, 2024

Omeros Corporation, Annual General Meeting, Jun 06, 2024

Omeros Corporation (NasdaqGM:OMER) announces an Equity Buyback for $50 million worth of its shares.

Omeros Corporation to Report Q4, 2023 Results on Apr 01, 2024

New major risk - Negative shareholders equity

Omeros Corporation to Report Q3, 2023 Results on Nov 09, 2023

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy

New minor risk - Market cap size

Omeros Corporation to Report Q2, 2023 Results on Aug 09, 2023

Omeros Corporation, Annual General Meeting, Jun 23, 2023

Kurt Zumwalt Not to Stand for Re-Election as Class II Director of Omeros Corporation

Omeros Corporation to Report Q1, 2023 Results on May 09, 2023

No longer forecast to breakeven

Insufficient new directors

Omeros Corporation to Report Q3, 2022 Results on Nov 09, 2022

Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial

Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab

Omeros Corporation to Report Q2, 2022 Results on Aug 09, 2022

First quarter 2022 earnings released: US$0.63 loss per share (vs US$0.57 loss in 1Q 2021)

Omeros Corporation to Report Q1, 2022 Results on May 10, 2022

No longer forecast to breakeven

Omeros Corporation, Annual General Meeting, Jun 17, 2022

Insufficient new directors

Insufficient new directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Insufficient new directors

Omeros Corporation to Report Q4, 2021 Results on Mar 01, 2022

Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA

Forecast to breakeven in 2024

Rayner Surgical Inc. completed the acquisition of OMIDRIA Franchise from Omeros Corporation (NasdaqGM:OMER).

Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.66 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$0.61 loss in 2Q 2020)

Omeros Corporation Announces Narsoplimab Pivotal Trial Data in Oral Presentation at 2021 Annual Congress of the European Hematology Association

Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906

Omeros Announces Preliminary Results from Additional Critically Ill COVID-19 Patients Treated with Narsoplimab

Omeros Corporation Announces Extension of U.S. Food and Drug Administration Review Period for Narsoplimab in HSCT-TMA

Omeros Corporation Announces Data on Organ Function Improvement from Omeros’ Pivotal Trial of Narsoplimab for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

First quarter 2021 earnings released: US$0.57 loss per share (vs US$0.54 loss in 1Q 2020)

Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration

Full year 2020 earnings released: US$2.42 loss per share (vs US$1.71 loss in FY 2019)

Revenue misses expectations

Omeros Corporation to Report Q4, 2020 Results on Mar 01, 2021

New 90-day high: €18.15

Omeros Corporation Appoints Nadia Dac as Its Chief Commercial Officer

New 90-day high: €16.20

Omeros Corporation Announces Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA

New 90-day high: €12.40

Omeros Corporation Announces Centers for Medicare & Medicaid Services Confirm Separate Payment for Omeros’ FDA-Approve OMIDRIA in Ambulatory Surgery Centers

New 90-day high: €11.37

Omeros Corporation Submits its Biologics License Application to U.S. FDA for Narsoplimab in HSCT-TMA

Third quarter 2020 earnings released: US$0.66 loss per share

Revenue beats expectations

Omeros Corporation to Report Q3, 2020 Results on Nov 09, 2020

Omeros Corporation to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMA

New 90-day low: €8.04

Omeros Corporation has completed a Follow-on Equity Offering in the amount of $100.05 million.

First half earnings released

New 90-day low - €11.27

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin